Healthcare entity
Every one of those 1 sits in a single category, market-trends. Chiesi Global Rare Diseases is the most frequent co-covered peer, appearing in 1 of the 1 tracked story. Source depth averages 2 original sources per story, versus 2.5 across the same-window beat baseline.
Last mentioned: Mar 18, 2026
Entity pulse
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
Every one of those 1 sits in a single category, market-trends. Chiesi Global Rare Diseases is the most frequent co-covered peer, appearing in 1 of the 1 tracked story. Source depth averages 2 original sources per story, versus 2.5 across the same-window beat baseline. At 5, the average consequence score sits below the same-window beat average of 5.8. We currently track 1 Healthcare story that mention Elfabrio, all published on March 18, 2026.
Computed from the 1 stories linked to this entity, with beat comparisons drawn from all 24 Healthcare stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering Elfabrio. Shared-story counts are live from our verified record — not editorial picks.
Protalix BioTherapeutics reported misses on both top-line and bottom-line estimates for the fiscal year 2026, reflecting ongoing challenges in the rare disease therapeutic market. Despite the shortfall, the company provided a forward-looking outlook for FY26, signaling a focus on long-term clinical development and commercialization of its plant-based protein expression platform.
Source: Seeking Alpha · Seeking Alpha
Elfabrio is linked from 1 story on this site, each scored at or above our 35% relevance threshold — see how these pages are built.
See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.
